Plavix duration of effect

Size: px
Start display at page:

Download "Plavix duration of effect"

Transcription

1 Plavix duration of effect The Borg System is 100 % Plavix duration of effect Jan 20, If you have had stent placement after balloon angioplasty for coronary artery disease you will be placed on medications to ensure you don't form clots inside those stents. One of them is aspirin, which you will take indefinitely after stent placement. The other one is up for debate, though most of you will take. Duration of clopidogrel (in combination with aspirin) after stent placement for ACS: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to.. Consumption of three 200 ml glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects. Alternative mechanisms may be responsible for the long-lasting effect of clopidogrel on platelet function. For example, the long elimination half-life of clopidogrel (>300 h for the [14C]- labelled drug, which was found predominantly in the plasma and not in blood cells [10], may contribute to its long duration of action. Medscape - Indication-specific dosing for Plavix (clopidogrel), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. Clopidogrel, sold as the brandname Plavix among others, is a medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). It is taken by mouth. Onset of effects is. 1 Answer - Posted in: plavix - Answer: The recommended daily dose of Plavix is 75 milligrams once a day. To give. (clopidogrel bisulfate) Tablets, for Oral Use. WARNING. DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE. The effectiveness of Plavix results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome. Clopidogrel (Plavix ) Prasugrel (Effient ) Ticagrelor (Brilinta ). Indications. - 1 and 2 prevention of stroke and MI. Duration. Load: mg. Maintenance: 80 or 81 mg

2 daily. Duration: Indefinite. Load: mg. Maintenance: 75 mg daily. Duration: ACS: up to 1 year. BMS: minimum 30 days. DES: minimum 1 year. Oct 11, Dual antiplatelet treatment (DAPT) is a cornerstone in the treatment of acute coronary syndrome (ACS) but the optimal treatment duration is unclear. We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Plavix; PA criteria: Plavix requires prior authorization for all members. Plavix therapy will be approved for members meeting approved diagnostic criteria that have failed aspirin therapy (due to either side effects or event recurrence), Is it safe to stop Plavix for surgery? Join this moderated discussion in our patient forum, and learn more. Plavix 75 mg film-coated tablets. Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate). Excipients with known effect: Each film-coated tablet contains 3 mg of lactose and 3.3 mg of hydrogenated castor oil. Plavix (Clopidogrel Bisulfate) is an anti-platelet drug designed to keep the platelets in your blood from clotting so that you don t develop blood clots. Clopidogrel, sold as the brandname Plavix among others, is a medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). Questions about dosage and length of treatment with Plavix (clopidogrel), Effient (prasugrel), and aspirin after having a stent? Have you experienced allergic reactions or side-effects?. Plavix official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. P2Y12 Resistance Units Percent Platelet Inhibition Receiver Operating Curve (Area Under Curve) % % % % % % 0.99 P2Y12 Receptor Antagonists Clopidogrel (Plavix ) Prasugrel (Effient ) Ticagrelor (Brilinta ) Cangrelor (Kengreal ) Prodrug Yes Yes No No Route Oral Oral Oral Intravenous. (clopidogrel bisulfate) Tablets, for Oral Use. WARNING. DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS-OF-FUNCTION ALLELES OF THE CYP2C19 GENE. The effectiveness of Plavix results

3 from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome. Medscape - Indication-specific dosing for Plavix (clopidogrel), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. 1 Answer - Posted in: plavix - Answer: The recommended daily dose of Plavix is 75 milligrams once a day. To give. Oct 11, Dual antiplatelet treatment (DAPT) is a cornerstone in the treatment of acute coronary syndrome (ACS) but the optimal treatment duration is unclear. We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS. Alternative mechanisms may be responsible for the long-lasting effect of clopidogrel on platelet function. For example, the long elimination half-life of clopidogrel (>300 h for the [14C]- labelled drug, which was found predominantly in the plasma and not in blood cells [10], may contribute to its long duration of action. Clopidogrel, sold as the brandname Plavix among others, is a medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). It is taken by mouth. Onset of effects is. Jan 20, If you have had stent placement after balloon angioplasty for coronary artery disease you will be placed on medications to ensure you don't form clots inside those stents. One of them is aspirin, which you will take indefinitely after stent placement. The other one is up for debate, though most of you will take. Duration of clopidogrel (in combination with aspirin) after stent placement for ACS: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to.. Consumption of three 200 ml glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects. Clopidogrel (Plavix ) Prasugrel (Effient ) Ticagrelor (Brilinta ). Indications. - 1 and 2 prevention of stroke and MI. Duration. Load: mg. Maintenance: 80 or 81 mg daily. Duration: Indefinite. Load: mg. Maintenance: 75 mg daily. Duration: ACS: up to 1 year. BMS: minimum 30 days. DES: minimum 1 year. Is it safe to stop Plavix for surgery? Join this moderated discussion in our patient forum, and learn more. Plavix (Clopidogrel Bisulfate) is an anti-platelet drug designed to keep the platelets in your blood from clotting so that you don t develop blood clots. Plavix 75 mg film-coated tablets. Each film-coated tablet

4 contains 75 mg of clopidogrel (as hydrogen sulphate). Excipients with known effect: Each film-coated tablet contains 3 mg of lactose and 3.3 mg of hydrogenated castor oil ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Plavix; PA criteria: Plavix requires prior authorization for all members. Plavix therapy will be approved for members meeting approved diagnostic criteria that have failed aspirin therapy (due to either side effects or event recurrence), P2Y12 Resistance Units Percent Platelet Inhibition Receiver Operating Curve (Area Under Curve) % % % % % % 0.99 P2Y12 Receptor Antagonists Clopidogrel (Plavix ) Prasugrel (Effient ) Ticagrelor (Brilinta ) Cangrelor (Kengreal ) Prodrug Yes Yes No No Route Oral Oral Oral Intravenous. Plavix official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. Questions about dosage and length of treatment with Plavix (clopidogrel), Effient (prasugrel), and aspirin after having a stent? Have you experienced allergic reactions or side-effects?. Clopidogrel, sold as the brandname Plavix among others, is a medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. Clopidogrel, sold as the brandname Plavix among others, is a medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). It is taken by mouth. Onset of effects is. Alternative mechanisms may be responsible for the long-lasting effect of clopidogrel on platelet function. For example, the long elimination half-life of clopidogrel (>300 h for the [14C]-labelled drug, which was found predominantly in the plasma and not in blood cells [10], may contribute to its long duration of action. Duration of clopidogrel (in combination with aspirin) after stent placement for ACS: Premature interruption of therapy may result in stent thrombosis with subsequent fatal and nonfatal MI. According to.. Consumption of three 200 ml glasses of grapefruit juice a day may substantially reduce clopidogrel antiplatelet effects. (clopidogrel bisulfate)

5 Tablets, for Oral Use. WARNING. DIMINISHED ANTIPLATELET EFFECT IN PATIENTS WITH TWO LOSS- OF-FUNCTION ALLELES OF THE CYP2C19 GENE. The effectiveness of Plavix results from its antiplatelet activity, which is dependent on its conversion to an active metabolite by the cytochrome. Clopidogrel (Plavix ) Prasugrel (Effient ) Ticagrelor (Brilinta ). Indications. - 1 and 2 prevention of stroke and MI. Duration. Load: mg. Maintenance: 80 or 81 mg daily. Duration: Indefinite. Load: mg. Maintenance: 75 mg daily. Duration: ACS: up to 1 year. BMS: minimum 30 days. DES: minimum 1 year. Jan 20, If you have had stent placement after balloon angioplasty for coronary artery disease you will be placed on medications to ensure you don't form clots inside those stents. One of them is aspirin, which you will take indefinitely after stent placement. The other one is up for debate, though most of you will take. 1 Answer - Posted in: plavix - Answer: The recommended daily dose of Plavix is 75 milligrams once a day. To give. Oct 11, Dual antiplatelet treatment (DAPT) is a cornerstone in the treatment of acute coronary syndrome (ACS) but the optimal treatment duration is unclear. We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS. Medscape - Indication-specific dosing for Plavix (clopidogrel), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Is it safe to stop Plavix for surgery? Join this moderated discussion in our patient forum, and learn more. Plavix official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. Learn about Plavix (Clopidogrel Bisulfate) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related medications. Clopidogrel, sold as the brandname Plavix among others, is a medication that is used to reduce the risk of heart disease and stroke in those at high risk. It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). Plavix; PA criteria: Plavix requires prior authorization for all members. Plavix therapy will be approved for members meeting approved diagnostic criteria that have failed aspirin therapy (due to either side effects or event recurrence), Questions about

6 dosage and length of treatment with Plavix (clopidogrel), Effient (prasugrel), and aspirin after having a stent? Have you experienced allergic reactions or side-effects?. Plavix (Clopidogrel Bisulfate) is an anti-platelet drug designed to keep the platelets in your blood from clotting so that you don t develop blood clots. Plavix 75 mg film-coated tablets. Each film-coated tablet contains 75 mg of clopidogrel (as hydrogen sulphate). Excipients with known effect: Each film-coated tablet contains 3 mg of lactose and 3.3 mg of hydrogenated castor oil. P2Y12 Resistance Units Percent Platelet Inhibition Receiver Operating Curve (Area Under Curve) % % % % % % 0.99 P2Y12 Receptor Antagonists Clopidogrel (Plavix ) Prasugrel (Effient ) Ticagrelor (Brilinta ) Cangrelor (Kengreal ) Prodrug Yes Yes No No Route Oral Oral Oral Intravenous. Contact Information Telephone or BORG (2674) FAX Postal address Minnetonka Industrial Rd. Minnetonka, MN Electronic mail General Information: West coast weight loss akron animal jam member hacks no survey Sitemap Thursday, July 29, 1999 This Site Has Been Visited Times.

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology

Antiplatelet and Anti-Thrombotic Therapy. Ivan Anderson, MD RIHVH Cardiology Antiplatelet and Anti-Thrombotic Therapy Ivan Anderson, MD RIHVH Cardiology Outline Anti-thrombotic therapy Risk stratification of stroke with atrial fibrillation DVT and PE treatment Pharmacology Anti-platelet

More information

Timing of Surgery After Percutaneous Coronary Intervention

Timing of Surgery After Percutaneous Coronary Intervention Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet

More information

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital

Guideline for STEMI. Reperfusion at a PCI-Capable Hospital MANSOURA. 2015 Guideline for STEMI Reperfusion at a PCI-Capable Hospital Mahmoud Yossof MANSOURA 2015 Reperfusion Therapy for Patients with STEMI *Patients with cardiogenic shock or severe heart failure

More information

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals. OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral

More information

325 mg aspirin and plavix

325 mg aspirin and plavix 325 mg aspirin and plavix 12-3-2006 Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for. Compare Aspirin

More information

Session Objectives. Clopidogrel Resistance. Clopidogrel (Plavix )

Session Objectives. Clopidogrel Resistance. Clopidogrel (Plavix ) Session Objectives New Antithrombotics and Real Time Genetic Testing: Their Role in the Vascular Patient Margaret C. Fang, MD, MPH Associate Professor of Medicine Division of Hospital Medicine Medical

More information

Learning Objectives. Epidemiology of Acute Coronary Syndrome

Learning Objectives. Epidemiology of Acute Coronary Syndrome Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet

More information

Optimal Duration of Dual Anti- Platelet Therapy. December 19, 2015

Optimal Duration of Dual Anti- Platelet Therapy. December 19, 2015 Optimal Duration of Dual Anti- Platelet Therapy December 19, 2015 John S. MacGregor, M.D., Ph.D. Professor of Medicine University of California San Francisco Source: The New Yorker 1 Optimal Duration of

More information

Synthroid interactions with food

Synthroid interactions with food Synthroid interactions with food The Borg System is 100 % Synthroid interactions with food You don't want to take ANY drugs or vitamins or supplements at the same time as you take your cream or milk is

More information

Nanik Hatsakorzian Pharm.D/MPH

Nanik Hatsakorzian Pharm.D/MPH Pharm.D/MPH 2014 1 Therapeutics FDA indication & Dosing Clinical Pearls Anticoagulants Heparin Antiphospholipid antibody syndrome Cerebral thromboembolism Prosthetic heart valve Acute coronary syndrome

More information

Thrombosis Research active studies

Thrombosis Research active studies Thrombosis Research active studies A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility

More information

Plavix eliquis and aspirin

Plavix eliquis and aspirin Plavix eliquis and aspirin The Borg System is 100 % Plavix eliquis and aspirin 273 medications are known to interact with Plavix. Includes amlodipine, aspirin, Aspirin Low Strength ( aspirin ). Eliquis

More information

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient

Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient For Immediate Release Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Takashi Shoda, President and Representative Director (Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

More information

Update on Antiplatelet Therapy

Update on Antiplatelet Therapy Update on Antiplatelet Therapy Christine Ibarra Pharm.D. PGY-1 Baptist Hospital of Miami Objectives Explain the role of antiplatelettherapy in prevention of cardiovascular events Appreciate differences

More information

Low dose depakote side effects

Low dose depakote side effects Low dose depakote side effects The Borg System is 100 % Low dose depakote side effects Oct 31, 2014. Studies also show if you take Depakote during pregnancy, your TEEN is at risk for having a lower IQ.

More information

Eliquis and plavix combination therapy

Eliquis and plavix combination therapy Eliquis and plavix combination therapy ELIQUIS Dosing for Patients With NVAF. patients treated with aspirin or the combination of bleeding or completion of a course of therapy,. 9-11-2011 Thrombosis is

More information

Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor

Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Oral Antiplatelet Therapy in Patients with ACS: A Focus on Prasugrel and Ticagrelor Nicolas W. Shammas, MS, MD, FACC Coronary and Peripheral Interventionalist Cardiovascular Medicine, PC Research Director,

More information

Prasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives

Prasugrel: Son of Clopidogrel or Distant Cousin? Disclosures. Objectives Prasugrel: Son of Clopidogrel or Distant Cousin? By John J. Bon, Pharm.D., BCPS Lead Clinical Pharmacist, Critical Care Summa Health System Disclosures I have no actual or potential conflict of interest

More information

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process

2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process Measure #204 (NQF 0068): Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY

More information

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI

The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI The Future of Oral Antiplatelets in PAD and CAD Christopher Paris, MD, FACC, FSCAI Interventional Cardiologist Cardiovascular Institute of the South Director of Cardiovascular Services St. Charles Parish

More information

ACCP Cardiology PRN Journal Club

ACCP Cardiology PRN Journal Club ACCP Cardiology PRN Journal Club 1 Optimising Crossover from Ticagrelor to Clopidogrel in Patients with Acute Coronary Syndrome [CAPITAL OPTI-CROSS] Monique Conway, PharmD, BCPS PGY-2 Cardiology Pharmacy

More information

amphetamines Will methylphenidate show as amphetamines

amphetamines Will methylphenidate show as amphetamines Will methylphenidate show as amphetamines The Borg System is 100 Will methylphenidate show as amphetamines How Long Does Methylphenidate Stay in Your panel for amphetamines, methylphenidate will show how

More information

Asif Serajian DO FACC FSCAI

Asif Serajian DO FACC FSCAI Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac

More information

Summary of the risk management plan (RMP) for Kengrexal (cangrelor)

Summary of the risk management plan (RMP) for Kengrexal (cangrelor) EMA/78859/2015 Summary of the risk management plan (RMP) for Kengrexal (cangrelor) This is a summary of the risk management plan (RMP) for Kengrexal, which details the measures to be taken in order to

More information

Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI

Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI Tailoring adjunctive antithrombotic therapy to reperfusion strategy in STEMI Adel El-Etriby; MD Professor of Cardiology Ain Shams University President of the Egyptian Working Group of Interventional Cardiology

More information

Doncaster & Bassetlaw Medicines Formulary

Doncaster & Bassetlaw Medicines Formulary Doncaster & Bassetlaw Medicines Formulary Section 2.9: Antiplatelet Drugs Aspirin 75mg Dispersible Tablets Aspirin 300mg Dispersible Tablets Aspirin 300mg Suppositories Clopidogrel 75mg Tablets Dipyridamole

More information

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None

Disclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to

More information

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015

Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic

More information

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.

DECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck. DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets

More information

Author: K. Ketchum Date: July 2015

Author: K. Ketchum Date: July 2015 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

DAPT Essential Messages from ESC Guidelines. Committee for Practice Guidelines

DAPT Essential Messages from ESC Guidelines. Committee for Practice Guidelines 2017 Essential Messages from ESC Guidelines Committee for Practice Guidelines DAPT Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease Essential Messages 2017 ESC focused update on dual

More information

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center

Antiplatelets and Anticoagulants. Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Antiplatelets and Anticoagulants Helen Leung, PharmD PGY1 Pharmacy Resident Memorial Hermann-Texas Medical Center Mechanism 2 http://www.medicinehack.com/2011/07/virchows-triad.html Mechanism 3 http://drtedwilliams.net/kb/index.php?pagename=coagulation%20cascade

More information

VerifyNow Reference Guide For use outside the U.S. only

VerifyNow Reference Guide For use outside the U.S. only VerifyNow Reference Guide For use outside the U.S. only VerifyNow P2Y12 Test Pre-surgical Application Studies show that there is patient variability in response to P2Y12 inhibitors 7. It has been recommended

More information

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in

More information

Paroxetine and the elderly

Paroxetine and the elderly Paroxetine and the elderly The Borg System is 100 % Paroxetine and the elderly Paroxetine, a antidepressant, is considered to have fewer side-effects than a typical tricyclic antidepressant. As the elderly

More information

Depakote and ammonia level

Depakote and ammonia level Depakote and ammonia level The Borg System is 100 % Depakote and ammonia level Sermo: What is the standard of care for handling hyperammonemia with Depakote? Physicians Only. Routine ammonia level is unnecessary,

More information

When and how to combine antiplatelet agents and anticoagulant?

When and how to combine antiplatelet agents and anticoagulant? When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation

More information

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management

Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures

More information

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS

6/1/18 LEARNING OBJECTIVES PATIENT POPULATION PRESENTATIONS PREVENTING HOSPITAL READMISSIONS IN CARDIOVASCULAR PATIENTS Christina Cortez Perry, MSN, FNP-C, CCCC Cardiology Coordinator- Corpus Christi Medical Center 1 2 LEARNING OBJECTIVES Identify the target patient

More information

Eliquis effect on inr prolongation 2017

Eliquis effect on inr prolongation 2017 Eliquis effect on inr prolongation 2017 The Borg System is 100 % Eliquis effect on inr prolongation 2017 Dec 17, 2016. Clin Chem Lab Med 2017; 55(8): e178 e180. Letter to the Editor. Tuukka A. Helin. prolongs

More information

Can i take indomethacin with aspirin

Can i take indomethacin with aspirin Can i take indomethacin with aspirin The Borg System is 100 % Can i take indomethacin with aspirin People who take nonsteroidal anti-inflammatory drugs (NSAIDs) (other than aspirin ) such as indomethacin

More information

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM

Bleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients

More information

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS

FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,

More information

Cytochrome P450 interactions

Cytochrome P450 interactions Cytochrome P450 interactions Learning objectives After completing this activity, pharmacists should be able to: Explain the mechanism of action of clopidogrel-ppi interaction Assess the risks and benefits

More information

Max naproxen dose for pulled muscle

Max naproxen dose for pulled muscle Max naproxen dose for pulled muscle The Borg System is 100 % Max naproxen dose for pulled muscle Naproxen is a medicine that reduces inflammation and pain in joints and muscles. It's used to treat diseases

More information

PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome

PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that

More information

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with American Association for Thoracic Surgery, American

More information

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά

Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Proposed Health Technology Appraisal NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Proposed Health Technology Appraisal Vorapaxar for the secondary prevention of atherothrombotic events after myocardial infarction Draft scope (pre-referral)

More information

PLAVIX 75mg film-coated tablets

PLAVIX 75mg film-coated tablets PACKAGE LEAFLET: INFORMATION FOR THE USER PLAVIX 75mg film-coated tablets CLOPIDOGREL This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which

More information

Ticagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome

Ticagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome DrUG FOrECAST Ticagrelor (Brilinta), an Antiplatelet Drug for Acute Coronary Syndrome raeanne Fuller, PharmD; and Benjamin Chavez, PharmD, BCPP INTRODUCTION Acute coronary syndrome (ACS) comprises myocardial

More information

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients

Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents

More information

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -

- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients - MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis

More information

- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e

- Mohammad Sinnokrot. -Ensherah Mokheemer. - Malik Al-Zohlof. 1 P a g e -1 - Mohammad Sinnokrot -Ensherah Mokheemer - Malik Al-Zohlof 1 P a g e Introduction Two of the most important problems you will face as a doctor are coagulation and bleeding, normally they are in balance,

More information

DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders

DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders DAPT in CAD, Acute & Chronic CAD, antiplatelet therapy non-responders Annual Ohio ACC Conference October 14, 2017 Ernest L. Mazzaferri Jr, MD, FACC, FSCAI Disclosures No financial disclosures related to

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

Non ST Elevation-ACS. Michael W. Cammarata, MD

Non ST Elevation-ACS. Michael W. Cammarata, MD Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar

More information

Dual Antiplatelet Therapy Made Practical

Dual Antiplatelet Therapy Made Practical Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor

More information

Controversies in Cardiac Pharmacology

Controversies in Cardiac Pharmacology Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?

More information

Pharmacogenomics with Clopidogrel: Does One Size Fit All?

Pharmacogenomics with Clopidogrel: Does One Size Fit All? Pharmacogenomics with Clopidogrel: Does One Size Fit All? Leah A. Sabato, PharmD PGY-1 Pharmacy Practice Resident UC Health - University of Cincinnati Medical Center leah.sabato@uchealth.com April 2015

More information

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)

Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,

More information

Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH

Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Goals and Objectives Discuss cardiac considerations for patients

More information

Aspirin paracetamol and ibuprofen together

Aspirin paracetamol and ibuprofen together Aspirin paracetamol and ibuprofen together The Borg System is 100 % Aspirin paracetamol and ibuprofen together 13-9-2017 Video bekijken Can you take paracetamol with ibuprofen? NHS reveals how you daily

More information

Pocket Guide. Antiplatelet Therapy in the Outpatient Setting 2011 Recommendations. Leadership. Knowledge. Community.

Pocket Guide. Antiplatelet Therapy in the Outpatient Setting 2011 Recommendations. Leadership. Knowledge. Community. Pocket Guide Antiplatelet Therapy in the Outpatient Setting 2011 Recommendations For more information, please visit the Canadian Cardiovascular Society (CCS) Antiplatelet Guidelines at www.ccsguidelineprograms.ca.

More information

Antiplatelet activity and the use of Cilostazol in Symptomatic ICAS Ameer E. Hassan DO

Antiplatelet activity and the use of Cilostazol in Symptomatic ICAS Ameer E. Hassan DO Antiplatelet activity and the use of Cilostazol in Symptomatic ICAS Ameer E. Hassan DO Assistant Professor of Neurology, Radiology, and Neurosurgery University of Texas Health Science Center - San Antonio

More information

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.

3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017

Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations

More information

Acetaminophen interaction with eliquis

Acetaminophen interaction with eliquis Acetaminophen interaction with eliquis The Borg System is 100 % Acetaminophen interaction with eliquis Apr 21, 2015. Common household painkillers may double the risk of bleeding associated with Eliquis..

More information

INDIVIDUALIZED MEDICINE

INDIVIDUALIZED MEDICINE CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic

More information

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017

Anticoagulation Management Around Endoscopy: GI Perspective. Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 Anticoagulation Management Around Endoscopy: GI Perspective Nathan Landesman, DO FACOI Flint Gastroenterology Associates October 11, 2017 EDUCATIONAL OBJECTIVES Understand risks of holding anticoagulation

More information

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?

Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013

More information

MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill.

MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill. MEDICATION GUIDE Prasugrel (pra-su-grel) tablets Read this Medication Guide before you start taking prasugrel and each time you get a refill. There may be new information. This Medication Guide does not

More information

ANTIPLATELET REGIMENS:

ANTIPLATELET REGIMENS: ANTIPLATELET REGIMENS: How Long, How Many? John Carter Hemphill, M.D., F.A.C.C. Chattanooga Heart Institute February 10, 2018 I have no financial disclosures. DISCLOSURES: OBJECTIVES Understand current

More information

Elements for a public summary. VI.2.1 Overview of disease epidemiology

Elements for a public summary. VI.2.1 Overview of disease epidemiology VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Coronary artery disease and as anticoagulant (inhibiting the clotting of the blood) in patients undergoing surgery to treat blockages

More information

Review Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes

Review Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes Review Article Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes Tirtha Patel V *, Jigna Shah S and Patel CN Department of Clinical Pharmacy, Shri Sarvajanik Pharmacy College, Mehsana, Gujarat,

More information

Medication Guide Plavix (PLAV-iks) (clopidogrel bisulfate) tablets

Medication Guide Plavix (PLAV-iks) (clopidogrel bisulfate) tablets Medication Guide Plavix (PLAV-iks) (clopidogrel bisulfate) tablets Read this Medication Guide before you start taking Plavix and each time you get a refill. There may be new information. This Medication

More information

Additional Contributor: Glenn Levine (USA).

Additional Contributor: Glenn Levine (USA). 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS) The Task Force for the Management

More information

A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI)

A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) A PRAGMATIC RANDOMIZED TRIAL OF CYP2C19 GENOTYPING IMPLEMENTATION FOLLOWING PERCUTANEOUS CORONARY INTERVENTION (PCI) Sony Tuteja, PharmD, MS Twitter @sony_tuteja Perelman School of Medicine at the University

More information

Canadian Antiplatelet Therapy Guidelines: 2014 Update James D. Douketis MD, FRCP(C)

Canadian Antiplatelet Therapy Guidelines: 2014 Update James D. Douketis MD, FRCP(C) Canadian Antiplatelet Therapy Guidelines: 2014 Update James D. Douketis MD, FRCP(C) Department of Medicine, St. Joseph s Healthcare Hamilton and McMaster University, Hamilton, Canada Disclosures for: James

More information

תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין

תרופות מעכבות טסיות חדשות דר אלי לב מנהל שרות הצנתורים ח השרון מרכז רפואי רבין תרופות מעכבות טסיות חדשות ד"ר אלי לב מנהל שרות הצנתורים ח השרון בי""י מרכז רפואי רבין 1. Why should clopidogrel be replaced? 2. Prasugrel 3. Ticagrelor 4. Conclusions CURE TRIAL ACS pts 20 % reduction

More information

The Dual Antiplatelet Therapy (DAPT) Trial: An FDA Perspective

The Dual Antiplatelet Therapy (DAPT) Trial: An FDA Perspective The Dual Antiplatelet Therapy (DAPT) Trial: An FDA Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological

More information

What s New in Antiplatelet Therapy and DES in 2016

What s New in Antiplatelet Therapy and DES in 2016 What s New in Antiplatelet Therapy and DES in 2016 Peter Pollak MD Director of Structural Heart Disease & Intervention Mayo Clinic Florida 2016 slide-1 Disclosures Financial None Off-label - None 2016

More information

Prostate Biopsy Alerts

Prostate Biopsy Alerts Prostate Biopsy Alerts Saskatchewan Prostate Assessment Pathway Guidelines for the Primary Care Provider for Patient Preparation and the Management of Medications and Complications September 2016 Table

More information

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events

Head-to-Head Study Showed Prasugrel Statistically Superior to Clopidogrel in Reducing Recurrent Cardiovascular Events Date: August 21, 2008 Refer to: Carole Copeland (OUS) Eli Lilly and Company 317-277-3661 (office) 317-610-6196 (cell) Tammy Hull (U.S.A.) Eli Lilly and Company 317-651-9116 (office) 317-614-5132 (cell)

More information

Adderall with alkaline water

Adderall with alkaline water Adderall with alkaline water The Borg System is 100 % Adderall with alkaline water Adderall, Adderall XR, and. Conversely, an acidic ph means the drug is predominantly in a water-soluble cationic highly

More information

SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable?

SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? SCA ST- : recommandations européennes 2015 La durée de la bithérapie : à géométrie variable? tielle est 2 ré Totielle est interdite. Prof. Marco Roffi Hôpitaux Universitaires de Genève Research funding

More information

Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved. 32 The Nurse Practitioner Vol. 41, No. 1

Copyright 2017 Wolters Kluwer Health, Inc. All rights reserved. 32 The Nurse Practitioner Vol. 41, No. 1 Abstract: New and more potent oral antiplatelet agents have shown better clinical outcomes over the last few years. This article reviews the latest oral antiplatelet therapies available, their indications

More information

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust

TRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current

More information

Disclosures. Updates in Acute Coronary Syndromes 10/21/17. No Conflicts of Interest. Updates in Acute Coronary Syndromes. Krishan Soni, MD, MBA, FACC

Disclosures. Updates in Acute Coronary Syndromes 10/21/17. No Conflicts of Interest. Updates in Acute Coronary Syndromes. Krishan Soni, MD, MBA, FACC Disclosures Updates in Acute Coronary Syndromes No Conflicts of Interest Krishan Soni, MD, MBA, FACC Assistant Professor of Medicine Division of Cardiology Krishan.soni@ucsf.edu Updates in Acute Coronary

More information

2010, Metzler Helfried

2010, Metzler Helfried Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What

More information

What hematologists should know about VerifyNow

What hematologists should know about VerifyNow What hematologists should know about VerifyNow Hematology fellows conference 12/13/2013 Presenter: Christina Fitzmaurice, MD, MPH Discussant: Daniel Sabath, MD, PhD HMC consult patient 54 yo woman admitted

More information

Preoperative antithrombotic management: before cardiac surgery. S. Demertzis

Preoperative antithrombotic management: before cardiac surgery. S. Demertzis Preoperative antithrombotic management: before cardiac surgery S. Demertzis Facts > CABG-related bleeding complications & perioperative acute coronary events are strongly influenced by the management of

More information

A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment

A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment A patient with an acute coronary syndrome one year ago. Options for antiplatelet treatment Ronen Durst, MD Cardiology Department Hadassah, Hebrew University Medical Center. Chairman, Israeli society for

More information

Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου

Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Dr Αντώνιος Στ. Ντάτσιος MSc, MRCP(UK), FESC. Επεμβατικός Καρδιολόγος Επιμελητής Β Γ. Ν. Θ. Παπαγεωργίου Θεσσαλονίκη, 9/2/2018 Disclosures: None Primary efficacy outcome* (%/year) Antiplatelet Therapy

More information

Is there enough evidence for DAPT after endovascular intervention for PAOD?

Is there enough evidence for DAPT after endovascular intervention for PAOD? Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...

More information

Anticoagulants and Antiplatelet. Therapy

Anticoagulants and Antiplatelet. Therapy Anticoagulants and Antiplatelet Therapy Your Heart and Blood Clots You ve been told by your healthcare provider that you have a condition that can cause blood clots. This may be due to several factors,

More information

Paroxetine and the elderly

Paroxetine and the elderly Paroxetine and the elderly The Borg System is 100 % Paroxetine and the elderly Doxepin >6mg/day (Silenor). Imipramine (Tofranil). Nortriptyline (Pamelor). Paroxetine (Paxil). Trimipramine (Surmontil).

More information

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center

Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes

More information

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017

Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Coronary Artery Disease (CAD) Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide is based on the 2017 KP National Coronary Artery Disease

More information

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke

The Challenge. Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Anticoagulation/Stroke Anticoagulation/Stroke Warfarin v new oral anticoagulants post PCI Warfarin or Novel Oral Anti-Coagulants in the PCI patient? Gerry Devlin Chairs: Phillip Matsis & Tony Scott Gerry Devlin Honorary Associate

More information